Printer Friendly

Coloplast's profit up by 5% in Q1 2018/19.

M2 PHARMA-February 6, 2019-Coloplast's profit up by 5% in Q1 2018/19

(C)2019 M2 COMMUNICATIONS

Coloplast A/S (CPH:COLOB), a medical device and related services company, reported on Tuesday net profit of DKK991m, or EPS of DKK4.66, for the first quarter of 2018/19, from 1 October 2018 to 31 December 2018.

This was a 5% increase over net profit of DKK940m, or EPS of DKK4.42, in Q1 2017/18.

Revenues for the quarter were DKK4,321m, up by 9% as compared with DKK3,955m in Q1 of 2017/18. Organic growth in the quarter was 8%.

Organic growth rates in the business areas for the quarter were 8% in Ostomy Care, 8%, in Continence Care, 9% in Interventional Urology and 11% in Wound & Skin Care 11%.

Also, there was solid growth during the quarter across all geographical regions, in particular Europe with 6% organic growth, driven by new product launches including SenSura Mio Convex and SpeediCath Flex.

In addition, the company provided financial guidance for 2018/19 and continues to expect organic revenue growth of 8% at constant exchange rates and a reported growth in DKK of 8% to 9%.

Further, Coloplast has expands its SpeediCath portfolio with the launch of SpeediCath Navi, a hydrophilic catheter specifically designed for emerging markets. This product will be launched during 2019 and 2020.

Coloplast A/S is a Danish multinational company that develops, manufactures and markets medical devices and services related to ostomy, urology, continence, and wound care.

(EUR1.00=DKK7.46)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Financial report
Date:Feb 6, 2019
Words:265
Previous Article:Pulmatrix Inc approves one for ten reverse common stock split.
Next Article:Arrevus acquires fusidic acid from Melinta Therapeutics for undisclosed amount.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters